Improving Access to Medicine
Story from UBS.
We took the lead in engaging with Takeda on their Access to Medicine (AtM) Strategy, as part of the Access to Medicine Foundation's collaborative engagement initiative. We identified several issues for engagement, including the expansion of equitable pricing strategies; project-specific access plans for late-stage projects; and enhancing transparency in relation to filling for market approvals.
Takeda has progressed on all engagement areas. It covers a large number of innovative medicines with its equity pricing strategies, having launched an initiative to ensure a systematic process is used for all late-stage projects to provide access plans and enhancements in relation to filing market approvals; noting that this is taking more time than they would have liked, considering the Shire integration. We were also pleased to learn about the company's collaboration with Duke University to create an Access to Health Impact Measurement Framework.
Takeda has disclosed that in 2019, 125,000 patients were supported with treatments to improve and extend lives, 4,000+ healthcare providers were trained and 1.1 million patients screened, as part of the company's holistic Access to Medicine approach.
Note that all fund impact stories are sourced from the fund manager and have not been independently verified by Ethos. You can view the source of this story here.
